The Deal
Saturday, November 21, 
1:11 am


Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
NOT A SUBSCRIBER?

Bristol's dance card

Posted on November 6, 2009 5:30 PM
At Bristol-Myers Squibb Co., the race is on to replace the pharmaceutical giant's biggest cash cow, the $6 billion-a-year moneymaker Plavix, a blood clot inhibitor whose patents expire in the first half of 2012.

James Cornelius, the drugmaker's chief executive, told analysts last month that Bristol has $1.3 billion in cash on hand and could soon have a further $1.75 billion as the result of a refinancing by Mead Johnson, in which Bristol still owns a majority stake.

This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence.


Dig deeper, with Pipeline.

  • 614 company pages related to Pharmaceuticals
  • 66 articles related to Mead Johnson
  • 28 in-depth transaction records for Bristol-Myers Squibb
  • 27 articles related to James Cornelius
  • 10 years of news and analysis archives from the voice of The Deal Economy


Most searched keywords
  • Deutsche Bank
  • Birds Eye
  • Cadbury AG
  • Agrium Inc.
  • Skadden Arps
  • Revolution Money
  • Tandberg ASA
  • Aisling Capital
  • Ken Lewis
  • Natco

EXISTING USERS


Username


Password


Forget your password?





Missing a product?



Sales Contact
Michael Crosby
mcrosby@thedeal.com
212.313.9325
Media Contact
Martha Brown
mbrown@thedeal.com
212.313.9218
Signing in signifies that you agree to our terms and conditions. View our privacy policy.